Auricular Vagal Neuromodulation for Chronic Kidney Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this pilot study is to establish the feasibility of home-based Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease (CKD) patients, generate preliminary efficacy data on autonomic function outcomes, and explore whether timing variation influences treatment response.
Who Is on the Research Team?
Qandeel Soomro, MD, MS
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
This trial is for people with chronic kidney disease who may have problems with their body's automatic functions, like heart rate or blood pressure. Specific inclusion and exclusion criteria are not listed, but participants must have CKD.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Auricular Vagal Neuromodulation Therapy (AVNT™)
Trial Overview
The study tests a device called Auricular Vagal Neuromodulation Therapy (AVNT™), which stimulates the ear to affect nerve activity. Some participants will use the real device at home, while others will use a sham (inactive) device for comparison.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Participants will use the active AVNT device for 1 hr/day at 7:00 PM.
Participants will use the active AVNT device for 1 hr/day at 7:00 AM.
Participants will use the sham-device for 1 hr/day at 7:00 AM.
Participants will use the sham-device for 1 hr/day at 7:00 PM.
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.